Healthcare Industry News: cardiac monitor
News Release - June 13, 2006
eCardio Diagnostics Launches eTrigger(TM) Monitor for Atrial FibrillationAuto Detect & Auto Trigger Features Identify Atrial Fibrillation in Asymptomatic Patients
THE WOODLANDS, Texas--(HSMN NewsFeed)--June 13, 2006--eCardio Diagnostics, LLC, a leading provider of advanced ambulatory cardiac monitoring products and services, announced today the launch of the eTrigger(TM) AF920 event monitor for detection of atrial fibrillation (Afib) among asymptomatic patients.
Unlike standard cardiac monitoring devices, eCardio Diagnostics eTrigger(TM) AF 920 is equipped with an embedded algorithm that automatically detects and records asymptomatic events without patient activation. This feature is especially valuable in diagnosing Afib as often times patients don't feel symptoms during an Afib episode.
Atrial fibrillation is the most common sustained heart rhythm disorder and increases the risk for heart disease and stroke, both leading causes of death in the United States(1). An estimated 2.2 million adults in the United States have been diagnosed with atrial fibrillation with an expected increase to over 5 million by 2040(2).
"We understand how difficult it can be to obtain a definitive diagnosis for an asymptomatic Afib patient. Through eCardio's rigorous research and testing process, we were able to pinpoint the most advanced auto-trigger technology to ensure our physician's could diagnose their Afib patients quickly and accurately," said Larry Lawson, President and CEO, eCardio Diagnostics.
eCardio Diagnostics will showcase its new eTrigger(TM) AF920 Afib Monitoring device at Pri-Med MidWest in Chicago, June 15-17. In addition to the new eTrigger(TM)AF920 monitor, eCardio will feature its other best-in-class holter, patient-activated and post-event monitors.
eCardio Diagnostics, LLC is a leading provider of advanced ambulatory cardiac monitoring products and services that improve the flexibility, speed and accuracy of arrhythmia diagnosis. For more information, visit the company's website at www.eCardio.com.
(1) Go, et al. JAMA 2002; 285:2370-2375
(2) Go, et al. JAMA 2001; 285:2370-2375
Source: eCardio Diagnostics
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.